GTx, Inc. is a company of pioneering and driven individuals who are delivering better medicines with new science through
established pathways. Our recognized scientific expertise is in the discovery and development of novel, selective small molecules
for the treatment of cancer, cancer supportive care, and other serious medical conditions.
Our most advanced drug discovery and development programs are focused on small molecules that selectively modulate the effects of estrogens and androgens.
GTx is developing enobosarm (Ostarine®;GTx-024), a selective androgen receptor
modulator, or SARM, for the prevention and treatment of muscle loss in patients
with non-small cell lung cancer and for other muscle wasting diseases.
GTx is also developing Capesaris® (GTx-758), a selective ER alpha agonist, as a hormonal therapy for men with advanced prostate cancer.